康芝药业收到止咳橘红颗粒药物临床试验批准通知书

Core Viewpoint - Kangzhi Pharmaceutical has received approval from the National Medical Products Administration for clinical trials of its product "Cough Orange Granules," which is already in production and sale [2]. Group 1 - The product "Cough Orange Granules" is a national secondary protected traditional Chinese medicine, with its protection period ending on September 13, 2016 [2]. - The current therapeutic functions of the product include "clearing the lungs, relieving cough, and resolving phlegm," specifically for cough with phlegm due to phlegm-heat obstructing the lungs, chest fullness, shortness of breath, and dry throat [2]. - The company has submitted a clinical trial application to add a new indication for "acute exacerbation of chronic obstructive pulmonary disease (COPD) with phlegm-heat obstructing the lungs" based on recent clinical research and expert consensus [2].